HANDELSBLATT EXCLUSIVE

Stada Chairman Won’t Rule Out Strategic Investor Bid

If the latest reports are to be believed, then the race to acquire Stada is starting to heat up.

The Chinese drugmaker Shanghai Fosun Pharma plans to enter the fray and make a bid for the Hesse-based drugmaker, sources told Reuters news agency. A bid from China would create a three-way competition for the mid-cap drugmaker, setting Stada up for a bidding war.

But Stada’s supervisory board chairman, Carl Ferdinand Oetker, couldn’t confirm to Handelsblatt on Thursday that Fosun intended to make an offer, though he also wouldn’t rule out a bid by a strategic investor.

“I’ve have also only read about it up until now,” Mr. Oetker told Handelsblatt. “We’ll see whether or not there will be other bidders. It can never be ruled out that a strategic investor comes at the end of such a process and makes an interesting offer. That’s also happened with finance investors.”

Two sources had told Reuters that Fosun Pharma is in discussions with the private equity firm CVC Capital Partners, headquartered in Luxembourg, to make a joint offer for Stada. Fosun could, however, decide to go at it alone in the end, the sources said.

A spokeswoman, talking to Reuters, had said Fosun has nothing to make public at this time.

Want to keep reading?

Subscribe today, and get access to distinguished coverage of Europe’s leading economy, from its No. 1 name in financial news: Handelsblatt.